Mesna
Pronunciation: (MEZ-nuh).
- Generic name
- mesna
- Brand names
- Uromitexan, Mesnex, Mesna
- Drug class
- Cytoprotective agent, Uroprotectant
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What mesna is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how mesna works
Mesna (2-mercaptoethane sulfonate sodium) acts as a uroprotectant by binding to and detoxifying acrolein and other urotoxic metabolites produced by oxazaphosphorine chemotherapy agents (ifosfamide, cyclophosphamide). It forms stable, non-toxic thioether compounds, preventing these metabolites from causing hemorrhagic cystitis and other bladder toxicities. (1)
What mesna is used for
Prevention of ifosfamide-induced hemorrhagic cystitis — the only FDA-approved indication
Prevention of ifosfamide-induced hemorrhagic cystitis — the only FDA-approved indication (2)
Prevention of cyclophosphamide-induced hemorrhagic cystitis — a common, well-established off-label use, but NOT a formally FDA-approved indication
Prevention of cyclophosphamide-induced hemorrhagic cystitis — a common, well-established off-label use, but NOT a formally FDA-approved indication (2)
Reduction of urothelial toxicity from oxazaphosphorine chemotherapy generally
Reduction of urothelial toxicity from oxazaphosphorine chemotherapy generally (2)
Before taking mesna
Do not take / not appropriate for
- Known hypersensitivity to mesna or any component of the formulation. (Contraindication) (2)
Tell your clinician about
(2)How to take mesna
- General Instructions: Mesna is usually given at the same time as, or shortly before and after, chemotherapy. It may be administered as an injection into a vein or taken by mouth as a tablet. Always follow your healthcare provider's instructions exactly.. Adult Dosing: Mesna is dosed as a percentage of the ifosfamide dose, not as a fixed amount. A common IV-only regimen is 20% of the ifosfamide dose given at the time of ifosfamide, then again at 4 and 8 hours after (total 60% of the ifosfamide dose) — for example, 400 mg/m² IV before chemotherapy followed by three 400 mg/m² post-doses would be typical for a particular ifosfamide dose level. A combined regimen also exists: 20% IV at time 0, then 40% oral tablets at 2 and 6 hours (total 100% of the ifosfamide dose). Your prescriber calculates the exact numbers from your specific ifosfamide dose.. Pediatric Dosing: Dosing in children is similar to adults and is calculated based on body surface area and chemotherapy dose. Your child's doctor will determine the exact schedule.. Administration: If taking oral tablets, swallow them whole with plenty of water. For injections, a healthcare professional will administer the dose. Drink extra fluids as directed to help protect your bladder.. If You Are Considering Stopping Early: Seek medical advice first; mesna is usually continued for several hours after chemotherapy is completed, and the clinician managing your chemotherapy can advise whether it is appropriate to stop early.. Storage: Store mesna tablets at 20-25°C (68-77°F), excursions permitted to 15-30°C, away from moisture and heat. If you are given injectable mesna at home, follow the storage instructions provided by your pharmacist.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (2)
Missed dose
If you miss a dose of mesna, contact your healthcare provider immediately for instructions. Do not take an extra dose without medical advice.
Overdose
In case of overdose, seek emergency medical attention or call your local poison control center. Symptoms may include nausea, vomiting, diarrhea, or allergic reactions. Supportive care is the mainstay of treatment. (2)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Nausea
Incidence: Reported in the clinician-authored database; frequency not established
Vomiting
Incidence: Reported in the clinician-authored database; frequency not established
Diarrhea
Incidence: Reported in the clinician-authored database; frequency not established
Headache
Incidence: Reported in the clinician-authored database; frequency not established
Abdominal pain
Incidence: Reported in the clinician-authored database; frequency not established
Rash
Incidence: Reported in the clinician-authored database; frequency not established
Hypersensitivity reactions
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
Serious hypersensitivity reactions, including anaphylaxis, can occur — symptoms may include fever, low blood pressure, and breathing distress — serious
Symptoms: Serious hypersensitivity reactions, including anaphylaxis, can occur — symptoms may include fever, low blood pressure, and breathing distress. Severe skin reactions have also been reported: drug rash with eosinophilia and systemic symptoms (DRESS), and bullous/ulcerative skin and mucosal reactions consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis. Report any new or worsening rash, blistering, or mucosal sores promptly.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Injectable mesna contains a benzyl alcohol preservative, which has been linked to fatal reactions and "gasping syndrome" in premature infants and neonates — relevant to how the injectable form is prepared and used in very young infants, a consideration for the treating team rather than the patient — serious
Symptoms: Injectable mesna contains a benzyl alcohol preservative, which has been linked to fatal reactions and "gasping syndrome" in premature infants and neonates — relevant to how the injectable form is prepared and used in very young infants, a consideration for the treating team rather than the patient.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Monitor for blood in urine during treatment — serious
Symptoms: Monitor for blood in urine during treatment. Not effective as a cancer treatment; only for bladder protection. Use with caution in patients with autoimmune disorders.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Contraindications — serious
Symptoms: Contraindications: known hypersensitivity to mesna or any excipient, including benzyl alcohol (injectable form). Precautions recorded in the clinician database: use with caution in patients with autoimmune disorders, history of allergic reactions, or those at risk for hypersensitivity. Monitor for skin and mucosal reactions, and ensure adequate hydration to maximize uroprotection.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Mesna is generally well-tolerated and has few significant drug interactions. However, it may interact with certain chemotherapy agents and other medications that affect the kidneys or bladder. Always inform your healthcare provider of all medicines, supplements, and herbal products you are taking. | (1) |
| Laboratory test interference (not a drug interaction, but relevant during treatment) | Mesna causes a false-positive result on urinary ketone tests, and may interfere with enzymatic creatine phosphokinase (CPK) activity assays. Your care team accounts for this when interpreting your lab results during treatment. | (2) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
No formal pregnancy category is established in the source material reviewed; the FDA label advises that female patients of reproductive potential use effective contraception during treatment and for 6 months after the last dose. Discuss pregnancy plans with the prescribing oncology team. (2)
Breastfeeding
Breastfeeding is advised against during mesna treatment and for 1 week after the last dose. (2)
Children
Frequency: Not recommended for pediatric use.. Weight Based: Not established; safety and effectiveness not established in pediatric patients.. Max Daily Dose: Not recommended for pediatric use.. Max Single Dose: Not recommended for pediatric use.. Age Restrictions: Safety not established in children. The injectable form contains benzyl alcohol, which has been linked to fatal reactions in premature infants/neonates specifically — a consideration for the treating team when mesna is used in very young children. (2)
Renal_impairment
No validated fixed dose-adjustment table for renal or hepatic impairment was found in the independent literature reviewed; dosing in organ impairment should be individualized by the treating oncology team with appropriate monitoring. (2)
Hepatic_impairment
No validated fixed dose-adjustment table for renal or hepatic impairment was found in the independent literature reviewed; dosing in organ impairment should be individualized by the treating oncology team with appropriate monitoring. (2)
Monitoring
(2)Storage
Store mesna tablets at 20-25°C (68-77°F), excursions permitted to 15-30°C, away from moisture and heat. If given injectable mesna at home, follow the storage instructions provided by your pharmacist.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General — FDA label (Mesnex), IV-only regimen
Indication: Prevention of ifosfamide-induced hemorrhagic cystitis
Dose summary: 20% (w/w) of the ifosfamide dose given IV at the time of ifosfamide, and again at 4 and 8 hours after (total 60% of the ifosfamide dose). E.g., 400 mg/m² IV before chemotherapy, then three 400 mg/m² post-doses, would be typical for a matching ifosfamide dose level — the DB's original example figures are retained here as an illustration of this percentage-based approach, not a universal fixed dose.
Renal context: No validated fixed renal-dose-adjustment table found; dosing individualized with monitoring. (2) (1)
General — FDA label (Mesnex), IV + oral regimen
Indication: Prevention of ifosfamide-induced hemorrhagic cystitis
Dose summary: 20% of the ifosfamide dose IV at time 0, then 40% as oral tablets at 2 and 6 hours after (total 100% of the ifosfamide dose).
Renal context: No validated fixed renal-dose-adjustment table found. (2)
Frequently asked questions
What is mesna used for?
Mesna is used to protect the bladder from harmful effects of certain chemotherapy drugs, such as ifosfamide and cyclophosphamide, which can cause bleeding and irritation in the urinary tract.
How does mesna work?
Mesna works by binding to toxic byproducts of chemotherapy drugs in the urine, neutralizing them and preventing damage to the bladder lining.
Can mesna cause side effects?
Yes, common side effects include nausea, vomiting, diarrhea, headache, and a metallic taste. Serious side effects like allergic reactions or blood in the urine are rare but require immediate medical attention.
Is mesna a chemotherapy drug?
No, mesna is not a chemotherapy drug. It is a protective agent used alongside certain chemotherapy medications to prevent bladder toxicity.
Can I take mesna if I am pregnant or breastfeeding?
Mesna should only be used during pregnancy or breastfeeding if clearly needed and prescribed by your doctor. Discuss risks and benefits with your healthcare provider.
What should I do if I miss a dose?
Contact your healthcare provider for instructions. Do not take an extra dose unless directed by your doctor.
How long do I need to take mesna?
Mesna is typically given before, during, and after chemotherapy sessions, as prescribed by your doctor. The duration depends on your chemotherapy schedule.
What happens if I take too much Mesna?
Taking too much Mesna can lead to an exacerbation of side effects, such as nausea, vomiting, diarrhea, and abdominal pain. While severe overdose is rare, it's crucial to contact your healthcare provider or seek emergency medical attention immediately if you suspect an overdose. They can provide guidance and monitor for any adverse reactions.
Can I drink alcohol while taking Mesna?
While there are no direct contraindications between Mesna and alcohol, it is generally advisable to limit or avoid alcohol consumption during chemotherapy treatment. Alcohol can worsen common side effects like nausea and vomiting, and may also interfere with the overall effectiveness of your cancer treatment. Always consult your healthcare provider for personalized advice regarding alcohol intake.
Is Mesna safe during pregnancy?
Mesna's safety during pregnancy has not been fully determined. The FDA label advises using effective contraception during treatment and for 6 months after the last dose, and avoiding breastfeeding during treatment and for 1 week after the last dose. It is crucial to consult your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding while considering or undergoing treatment with Mesna. They can assess the potential risks and benefits and recommend the most appropriate course of action.
What is the mechanism of action of mesna?
Mesna (2-mercaptoethane sulfonate sodium) acts as a uroprotectant by binding to and detoxifying acrolein and other urotoxic metabolites produced by oxazaphosphorine chemotherapy agents (ifosfamide, cyclophosphamide). It forms stable, non-toxic thioether compounds, preventing these metabolites from causing hemorrhagic cystitis and other bladder toxicities. (1)
What is the generic name of Mesna?
The generic name is mesna. It is sold under brand names including Uromitexan, Mesnex, Mesna.
What class of drug is mesna?
Mesna is classed as: Cytoprotective agent, Uroprotectant.
References
- Mesna — clinician-authored medicine recordMedGuideGlobal internal clinician-authored medicine record · International (internal record) · dated 2026 · accessed 2026-08-06 · source 1
- MESNEX (mesna injection) prescribing informationU.S. Food and Drug Administration · United States · dated 2026 · accessed 2026-08-06 · source 2
- MESNEX (MESNA) TABLET, FILM COATED [BAXTER HEALTHCARE COMPANY] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 3
- Mesna — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 4
- MESNEX — FDA approval record (Drugs@FDA NDA019884)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 5
- mesna — RxNorm normalized drug concept (RXCUI 44)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 6
Brand names by country
Single-ingredient mesna names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- MESNEX100 mg/mL, 400 mg · bamboo us bidco lcc
Canada
- UROMITEXAN